{"denoms":[{"counts":[{"groupId":"BG000","value":"33"}],"units":"Participants"}],"groups":[{"description":"Participants with symptomatic untreated low grade NHL will be treated according to a 28 day schedule for up to a maximum of 12 consecutive cycles:\n\n375 mg/m\\^2 Rituximab IV on day 1.\n\n20 mg Lenalidomide taken orally on days 1-21.\n\n250 mg/m\\^2 Cyclophosphamide orally on days 1, 8, 15.\n\n40 mg Dexamethasone orally on days 1, 8, 15, 22.","id":"BG000","title":"Treatment"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"43","upperLimit":"83","value":"68"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"24"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}